Pacira BioSciences posted $726.4 million in total revenue for 2025 — a record — yet it still needs a proxy fight to defend its own boardroom. That tension is the actual story here. A relatively small activist, DOMA Perpetual Capital Management, is contesting three seats at the June 9 annual meeting, forcing a company that just delivered 79.4% GAAP gross margins and returned to GAAP profitability to spend shareholder capital on letters, BLUE proxy cards, and public rebuttals instead of executing the diversification strategy it claims is working.
The underlying business case Pacira is making is genuinely coherent. EXPAREL volume growth accelerated from 3.6% in 2024 to 6.2% in 2025, with the back half running at 8% — a real inflection, not a statistical blip. The 2025 EXPAREL patent settlement with Fresenius Kabi locks in full exclusivity through 2030 and a capped generic transition through 2039, which is a materially better outcome than the binary cliff that patent litigation usually produces. Add the J&J MedTech and LG Chem partnerships, PCRX-201 in Phase 2 for knee osteoarthritis, and a recently in-licensed ropivacaine asset (PCRX-2002), and the 5×30 roadmap has identifiable pillars rather than aspirational hand-waving.
But a 31% stock gain since strategy launch is a relative metric that obscures where the stock actually sits — still well below its 2021 highs, still a single-product-dependent company by revenue concentration, and still reliant on EXPAREL’s protected window to buy time for pipeline maturation. DOMA’s critique, whatever its accuracy, lands in that context. Activist pressure at a company with a credible new CEO (Frank Lee, appointed 2024), improving fundamentals, and a defined five-year plan is an odd strategic moment for a board shake-up — which may be precisely why Pacira’s defense sounds confident rather than panicked.
The single outcome worth tracking is the Phase 2 data readouts Pacira has flagged for late 2026, specifically PCRX-201 in osteoarthritis. A clean signal there does more to silence DOMA’s thesis than any proxy vote — because it converts the 5×30 narrative from a commercial restructuring story into a pipeline story with real pricing power beyond the EXPAREL franchise window.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
